Clinical Report: Solving the Problem of Insolubility: Part II

Overview

This report discusses the KinetiSol technology developed to address the challenges of drug solubility in pharmaceutical manufacturing. The process enables the efficient transformation of poorly soluble drugs into a more bioavailable form, potentially enhancing therapeutic outcomes.

Background

The solubility of drugs is a critical factor in their bioavailability and therapeutic efficacy. As drug discovery evolves, particularly with complex molecules, traditional formulation methods often fall short. Innovative solutions like KinetiSol are essential to overcome these challenges and facilitate the development of previously undruggable compounds.

Data Highlights

No numerical data or trial data was provided in the article.

Key Findings

• KinetiSol technology efficiently transforms poorly soluble drugs into amorphous dispersions.
• The process utilizes mechanical energy to dissolve drug crystals without the need for solvents.
• It can handle drugs with high melting points, which are typically challenging to formulate.
• The resulting product has improved solubility and dissolution properties compared to traditional methods.
• KinetiSol is positioned as a solution for molecules with significant therapeutic potential but poor physicochemical properties.

Clinical Implications

Healthcare professionals should be aware of the advancements in drug formulation technologies like KinetiSol, which may improve the therapeutic efficacy of challenging compounds. Understanding these innovations can aid in the selection of appropriate therapies for patients with conditions requiring poorly soluble medications.

Conclusion

KinetiSol represents a significant advancement in the manufacturing of insoluble drugs, offering a pathway to enhance their clinical utility. Continued exploration of such technologies is vital for the future of drug development.

References

1. the medicine maker, Source, 2026 -- Solving the Problem of Insolubility: Part I
2. Impact of Theobromine on the Dissolution of Uric Acid Kidney Stones, Source, 2022
3. the analytical scientist, Source, 2026 -- The Secret Life of a Solvent
4. ICH M13B Webinar: Navigating the Draft ICH M13B Additional Strengths Biowaiver Guideline - 09/11/2025 | FDA
5. Changes in drug crystallinity in a commercial tacrolimus amorphous formulation result in variable pharmacokinetics - PubMed
6. Acta Neuropathologica — Response: Are Soluble Oligomers or Insoluble Fibrils the Key Players?
7. ICH M13B Webinar: Navigating the Draft ICH M13B Additional Strengths Biowaiver Guideline - 09/11/2025 | FDA
8. Changes in drug crystallinity in a commercial tacrolimus amorphous formulation result in variable pharmacokinetics - PubMed
9. Fiscal Year 2025 Generic Drug Science and Research Initiatives Public Workshop - 06/03/2025 | FDA